Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Pyme británica ofrece una formulación farmacéutica para el tratamiento del cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOUK20190801001
Publicado:
27/08/2019
Caducidad:
27/08/2020
Resumen:
Una pyme británica ha desarrollado una nueva formulación de entidades químicas debidamente caracterizadas que desenmascara lugares clave en células tumorales, haciendo que sean más vulnerables a diversos tratamientos del cáncer dirigidos y, por lo tanto, ayudando a superar el problema de resistencia. Esta formulación también ha demostrado tener su propia actividad como monoterapia en diferentes tumores. La formulación inhibe las vías de señalización celular que contribuyen al desarrollo y evolución del cáncer. La empresa busca grandes compañías farmacéuticas que trabajen en el sector de oncología para realizar los primeros ensayos clínicos en humanos con vistas a la reglamentación y comercialización de la formulación. La cooperación se establecerá en el marco de un acuerdo de joint venture o licencia.

Details

Tittle:
UK-based SME offers its pharmaceutical formulation for treatment of cancer
Summary:
A UK-based SME has developed a novel formulation of well-characterised chemical entities that renders cancer cells resistant to range of targeted cancer treatments vulnerable to these treatments again. In addition it also works as a therapy in a range of tumours in its own right. The SME is looking to partner with larger pharmaceutical companies for first in human and clinical trials. It is envisaged that the partnership will be either a joint venture or a licensing agreement.
Description:
Cancer is the second leading cause of death globally despite great strides being made in both the detection and treatment of the disease. One of the issues is resistance to first line chemotherapy developing.

A UK-based SME has developed a formulation based on well characterised chemical entities that unmasks key sites on tumour cells making them more vulnerable to a range of targeted cancer treatments and so overcoming the problem of resistance. It has also been shown to have its own activity as a mono therapy in a range of tumours. The formulation has generated promising data in pre-clinical studies and the SME is looking to move development forwards into first in human trials.

The SME is looking to partner with a larger pharmaceutical company operating in the field of oncology that would be able to carry out the first in human trials with a view to regulation and commercialisation of the formulation. It is envisaged that the partnership will take the form of a joint venture. Alternatively the UK SME will consider licensing the technology to the partner company if that better suits both parties.
Advantages and Innovations:
The UK SME´s formulation has the following advantages:

1. Inhibits the cell signalling pathways that lead to cancer development and progression.

2. Renders a range of targeted cancer treatments effective by unmasking key sites on tumour cells.

3. Has activity against a range of tumours as a mono therapy.

4. It testing carried out to date the formulation shows low toxicity and low level of side effects.
Stage of Development:
Under development/lab tested
IPs:
Secret Know-how,Patents granted

Partner sought

Type and Role of Partner Sought:
The UK SME is looking to partner with larger pharmaceutical companies operating in oncology sector. In particular the partner must be able to take the SMEs formulation from its current pre-clinical stage through first in human and preferably subsequent clinical trials to commercialisation.

The partnership is expected to take the form of either a joint venture or a licensing agreement, dependent on which is most beneficial to both parties.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología